408 related articles for article (PubMed ID: 22911440)
41. [Clinical characteristics of children with B cell type acute lymphoblastic leukemia carrying different fusion gene].
Zuo YX; Zhang LP; Lu AD; Wang B; Liu GL
Zhongguo Dang Dai Er Ke Za Zhi; 2010 Mar; 12(3):172-6. PubMed ID: 20350423
[TBL] [Abstract][Full Text] [Related]
42. Genetic evaluation of childhood acute lymphoblastic leukemia in Iraq using FTA cards.
Al-Kzayer LF; Sakashita K; Matsuda K; Al-Hadad SA; Al-Jadiry MF; Abed WM; Abdulkadhim JM; Al-Shujairi TA; Hasan JG; Al-Abdullah HM; Al-Ani MH; Saber PA; Inoshita T; Kamata M; Koike K
Pediatr Blood Cancer; 2012 Sep; 59(3):461-7. PubMed ID: 22238115
[TBL] [Abstract][Full Text] [Related]
43. [Evaluation on protocol SCMS-ALL-2005 for childhood B lineage acute lymphoblastic leukemia].
Tang JY; Xue HL; Chen J; Pan C; Li BS; Gu LJ; Dong L; Hu WT; Shen SH; Zhou M; Ye QD; Jiang H; Luo CY
Zhonghua Yi Xue Za Zhi; 2012 Feb; 92(8):546-50. PubMed ID: 22490159
[TBL] [Abstract][Full Text] [Related]
44. The therapeutic efficacy of pediatric ALL patients with MLL gene rearrangement treated with CCLG-ALL2008 protocol.
Sun YN; Hu YX; Gao L; Xiao PF; Lu J; Wu SY; Wang M; Shao XJ; Zhou CY; Ling J; Li JQ; Pan J; Gao J; Hu SY
Eur Rev Med Pharmacol Sci; 2018 Sep; 22(18):6020-6029. PubMed ID: 30280786
[TBL] [Abstract][Full Text] [Related]
45. Low expressions of ARS2 and CASP8AP2 predict relapse and poor prognosis in pediatric acute lymphoblastic leukemia patients treated on China CCLG-ALL 2008 protocol.
Cui L; Gao C; Zhang RD; Jiao Y; Li WJ; Zhao XX; Liu SG; Yue ZX; Zheng HY; Deng GR; Wu MY; Li ZG; Jia HT
Leuk Res; 2015 Feb; 39(2):115-23. PubMed ID: 25530566
[TBL] [Abstract][Full Text] [Related]
46. Persistence of TEL-AML1 transcript in acute lymphoblastic leukemia in long-term remission.
Endo C; Oda M; Nishiuchi R; Seino Y
Pediatr Int; 2003 Jun; 45(3):275-80. PubMed ID: 12828580
[TBL] [Abstract][Full Text] [Related]
47. Ikaros (IKZF1) alterations and minimal residual disease at day 15 assessed by flow cytometry predict prognosis of childhood BCR/ABL-negative acute lymphoblastic leukemia.
Volejnikova J; Mejstrikova E; Dörge P; Meissner B; Zimmermannova O; Svojgr K; Stanulla M; Cario G; Schrappe M; Stary J; Hrusak O; Trka J; Fronkova E
Pediatr Blood Cancer; 2013 Mar; 60(3):420-7. PubMed ID: 22997141
[TBL] [Abstract][Full Text] [Related]
48. Prevalence of common fusion transcripts in acute lymphoblastic leukemia: A report of 304 cases.
Chopra A; Soni S; Verma D; Kumar D; Dwivedi R; Vishwanathan A; Vishwakama G; Bakhshi S; Seth R; Gogia A; Kumar L; Kumar R
Asia Pac J Clin Oncol; 2015 Dec; 11(4):293-8. PubMed ID: 26264145
[TBL] [Abstract][Full Text] [Related]
49. NOTCH1 mutations are associated with favourable long-term prognosis in paediatric T-cell acute lymphoblastic leukaemia: a retrospective study of patients treated on BCH-2003 and CCLG-2008 protocol in China.
Gao C; Liu SG; Zhang RD; Li WJ; Zhao XX; Cui L; Wu MY; Zheng HY; Li ZG
Br J Haematol; 2014 Jul; 166(2):221-8. PubMed ID: 24690100
[TBL] [Abstract][Full Text] [Related]
50. Expression of TEL-AML1 fusion transcripts and response to induction therapy in standard risk acute lymphoblastic leukemia.
Uckun FM; Pallisgaard N; Hokland P; Navara C; Narla R; Gaynon PS; Sather H; Heerema N
Leuk Lymphoma; 2001 Jun; 42(1-2):41-56. PubMed ID: 11699220
[TBL] [Abstract][Full Text] [Related]
51. The prognostic role of E2A-PBX1 expression detected by real-time quantitative reverse transcriptase polymerase chain reaction (RQ-PCR) in B cell acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation.
Hong Y; Zhao X; Qin Y; Zhou S; Chang Y; Wang Y; Zhang X; Xu L; Huang X
Ann Hematol; 2018 Sep; 97(9):1547-1554. PubMed ID: 29705861
[TBL] [Abstract][Full Text] [Related]
52. A prospective evaluation of minimal residual disease as risk stratification for CCLG-ALL-2008 treatment protocol in pediatric B precursor acute lymphoblastic leukemia.
Hu YX; Lu J; He HL; Wang Y; Li JQ; Xiao PF; Li J; Lv H; Sun YN; Fan JJ; Chai YH; Hu SY
Eur Rev Med Pharmacol Sci; 2016 May; 20(9):1680-90. PubMed ID: 27212157
[TBL] [Abstract][Full Text] [Related]
53. Long-Term Results of the Risk-Stratified Treatment of TCF3-PBX1-Positive Pediatric Acute Lymphoblastic Leukemia in China.
Wang Y; Xue YJ; Lu AD; Jia YP; Zuo YX; Zhang LP
Clin Lymphoma Myeloma Leuk; 2021 Feb; 21(2):e137-e144. PubMed ID: 33221150
[TBL] [Abstract][Full Text] [Related]
54. [Correlation of E2a-pbx1 expression level with clinical characteristics and early response to treatment in children with acute lymphoblastic leukemia].
Gao C; Li ZG; Zhao W; Wu MY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Jun; 16(3):569-73. PubMed ID: 18549631
[TBL] [Abstract][Full Text] [Related]
55. [Real-time quantitative detection of E2A-PBX1 fusion gene in children with acute lymphoblastic leukemia and its clinical application in minimal residual disease monitoring].
Zhang R; Liao J; Li G; Sun HQ; Shi YJ; Yang JY
Zhongguo Dang Dai Er Ke Za Zhi; 2013 Jun; 15(6):440-3. PubMed ID: 23791058
[TBL] [Abstract][Full Text] [Related]
56. Clinical features and prognostic impact of TCF3-PBX1 in childhood acute lymphoblastic leukemia: A single-center retrospective study of 837 patients from China.
Jia M; Hu BF; Xu XJ; Zhang JY; Li SS; Tang YM
Curr Probl Cancer; 2021 Dec; 45(6):100758. PubMed ID: 34034913
[TBL] [Abstract][Full Text] [Related]
57. Early MRD response as a prognostic factor in adult patients with acute lymphoblastic leukemia.
Šálek C; Folber F; Froňková E; Procházka B; Marinov I; Cetkovský P; Mayer J; Doubek M;
Eur J Haematol; 2016 Mar; 96(3):276-84. PubMed ID: 25997106
[TBL] [Abstract][Full Text] [Related]
58. [A comparison of minimal residual disease in children with acute lymphoblastic leukemia of different genetic abnormalities].
Huang SY; Jia YP; Liu GL; Zhang LP; Lu AD; Wang B
Zhongguo Dang Dai Er Ke Za Zhi; 2014 May; 16(5):494-8. PubMed ID: 24856999
[TBL] [Abstract][Full Text] [Related]
59. Clinical heterogeneity in childhood acute lymphoblastic leukemia with 11q23 rearrangements.
Pui CH; Chessells JM; Camitta B; Baruchel A; Biondi A; Boyett JM; Carroll A; Eden OB; Evans WE; Gadner H; Harbott J; Harms DO; Harrison CJ; Harrison PL; Heerema N; Janka-Schaub G; Kamps W; Masera G; Pullen J; Raimondi SC; Richards S; Riehm H; Sallan S; Sather H; Shuster J; Silverman LB; Valsecchi MG; Vilmer E; Zhou Y; Gaynon PS; Schrappe M
Leukemia; 2003 Apr; 17(4):700-6. PubMed ID: 12682627
[TBL] [Abstract][Full Text] [Related]
60. Risk group assignment differs for children and adults 1-45 yr with acute lymphoblastic leukemia treated by the NOPHO ALL-2008 protocol.
Toft N; Birgens H; Abrahamsson J; Bernell P; Griškevičius L; Hallböök H; Heyman M; Holm MS; Hulegårdh E; Klausen TW; Marquart HV; Jónsson OG; Nielsen OJ; Quist-Paulsen P; Taskinen M; Vaitkeviciene G; Vettenranta K; Åsberg A; Schmiegelow K
Eur J Haematol; 2013 May; 90(5):404-12. PubMed ID: 23461707
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
